Slone Partners Recruits CEO for the Personalized Medicine Coalition
November 25, 2024 – Life sciences-focused search firm Slone Partners has assisted in the recruitment of Amy Nicole Nayar as the new president and CEO of the Personalized Medicine Coalition (PMC) in South Riding, VA. She will begin her tenure on January 1, 2025. “We are excited about this placement as part of our long term partnership with the talented PMC team,” said Leslie Loveless, managing partner and CEO of Slone Partners. “I cannot overstate the critical nature of PMC’s work educating patients and decisionmakers on how personalized medicine can make healthcare far more efficient and effective, and we are honored to partner with them to achieve even greater success in the coming years.”
“Amy Nicole Nayar is a tremendously accomplished leader known for her strategic approach to harnessing the resources necessary to drive collective impact, aligning well with PMC’s resolve to use patient-centric frameworks and diagnostics to intervene early and improve patient outcomes,” said Kim Wilson, senior vice president, executive search and partner at Slone Partners. “With an extremely successful track record over more than 25 years in the global health industry, Dr. Nayar will bring a valuable blend of clinical insight and technological understanding to PMC.”
“Under the leadership of Amy Nicole Nayar, the PMC board of directors is confident that the Coalition will significantly expand its influence and impact in education, advocacy, and evidence development for the benefit of patients and health systems around the world,” said PMC board chairman Lincoln Nadauld. “We look forward to working with her to strengthen the Coalition and advance personalized medicine.”
A pioneering leader in the field, Dr. Nayar has experience in creating patient-centered change by connecting and mobilizing stakeholders from industry, government, patient communities, and clinical settings. She advocates for integrated healthcare transformation, fostering collaborations, encouraging adaptive thinking, and championing solution-focused initiatives to set new benchmarks in patient care.
Currently, Dr. Nayar serves as vice president for U.S. patient advocacy & government affairs at Novartis Gene Therapies. In this position, she collaborates to streamline genetic testing and treatment pathways, paving the way for patients to benefit from some of the world’s most innovative personalized treatments. During her career, Dr. Nayar has held senior executive roles at Pfizer, AbbVie, and Porter Novelli.
“I am deeply honored to join forces with PMC’s esteemed members to advance our collective mission,” said Dr. Nayar. “Today’s breakthroughs in AI and genomic science are revolutionizing our approach to health care, enabling us to intervene earlier, tailor treatments, and return value to the system. Together, we will advance health care systems that are more precise, preventive, and aligned with patient needs.”
The Personalized Medicine Coalition, a 501(c)3-designated non-profit organization comprised of 13 distinct stakeholder groups within healthcare, promotes the understanding and adoption of personalized medicine concepts, services, and products to benefit patients and health systems. It provides a forum for achieving consensus and informing policies that support personalized medicine.
Serving the Healthcare & Life Sciences Sectors
Slone Partners is a nationally recognized senior-level recruitment provider that specializes in delivering executive, management, and leadership talent for the diagnostic, biopharmaceutical, healthcare information technology, and laboratory testing industries. The firm has offices in Boston, New York, Washington, D.C., and San Francisco. Recently, Slone Partners was included among Hunt Scanlon Media’s “Top 50 Healthcare & Life Sciences Search Firms.”
Related: Slone Partners Recruits Chief Medical Officer for Carisma Therapeutics
In 2000, Adam Slone founded Slone Partners and acted as CEO from 2000 to 2016. He remains chairman today. His industry knowledge and extensive contacts have enabled Slone Partners to place thousands of executives and industry professionals. Today, Mr. Slone remains engaged with Slone Partners, with a specific focus in strategy, finance, M&A advisement, and business development in Boston and California.
Ms. Loveless has nearly 20 years of healthcare industry and executive search experience to Slone Partners. She joined the firm in 2007, became COO in 2014 and CEO in 2016. At Slone Partners, Ms. Loveless acts as the leader of the organization as well as the head of the executive search team. Her involvement with clients and candidates enables her to understand the key motivations of each. As CEO, Ms. Loveless’ focus extends to cultivating new business partnerships and expanding relationships with existing clients. Through her leadership, life sciences and biotechnology have emerged as the primary client base for Slone Partners.
Ms. Wilson has more than 20 years of experience in the healthcare and life sciences industries. She finds senior talent in the biotech, life sciences, diagnostics, healthcare, digital health, and medical technology sectors. Ms. Wilson recruits leaders in the areas of operations, finance, commercialization, legal, clinical, scientific, reimbursement, regulatory affairs, and more. She places key strategic leaders from the VP level to the C-suite and boardroom. Prior to joining Slone Partners, she worked in commercial roles with Quest Diagnostics, Cardinal, and McKesson.
Related: Slone Partners Recruits Chief Business Officer for Arpeggio Biosciences
Contributed by Scott A. Scanlon, Editor-in-Chief and Dale M. Zupsansky, Executive Editor – Hunt Scanlon Media
